CA
NZ
UK
AU
IND
US
Virtuix Holdings Inc. Has entered into a strategic partnership with Sirica Therapeutics aimed at revolutionizing autism therapy through artificial intelligence. This collaboration follows the initial deployment of Virtuix's Omni One systems, which are designed to create movement-centered virtual reality experiences specifically for children with …
Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares declined in trading today despite the company announcing encouraging clinical progress for its investigational anti-interleukin-15 antibody in vitiligo. Teva is a Tel Aviv, Israel-based global leader in generic and specialty pharmaceutical manufacturing, supplying products across more than 100 …
Turn Therapeutics, Inc. (NASDAQ:TTRX) shares surged in trading today after the company announced the completion of a comprehensive interim analysis of its adaptive Phase 2 trial evaluating GX-03 for atopic dermatitis. Turn Therapeutics is a Westlake Village, California-based clinical-stage biotechnology company developing targeted, non-systemic …
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) shares surged in trading today after the company announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor designed as a phosphate prodrug of its earlier compound, TTI-101. Tvardi is a Houston, Texas-based clinical-stage biopharmaceutical company developing oral small molecule …
ClearOne, Inc. (NASDAQ:CLRO) shares surged in trading today as investor interest built around the company's pending merger with Cortigent, a developer of brain implant devices designed to help patients recover sight and motor function. ClearOne is a Salt Lake City-based company that recently divested …
Tvardi Therapeutics (NASDAQ: TVRD) issued a corporate announcement presenting results from the first-in-human study of its investigational candidate TTI‑109. The data validate the drug’s engineered prodrug architecture and provide early signs of its potential.
U.S. Physical Therapy (NYSE: USPH) has broadened its outpatient footprint by adding a 12‑location physical therapy provider. The transaction, recently completed, reinforces the company’s presence in the expanding rehabilitation services market and aligns with its growth strategy that emphasizes selective acquisitions.
Vaxart Inc. (OTC: VXRT) announced topline safety findings from its Phase 2b clinical trial, indicating that the oral COVID‑19 vaccine candidate did not raise serious safety flags. The investigation contrasted the pill formulation with an authorized mRNA vaccine within an approximately 400‑participant sentinel safety …
Vera Therapeutics (NASDAQ: VERA) has achieved a major regulatory milestone with the U.S. Food and Drug Administration’s accelerated approval of its drug TRUTAKNA. The decision highlights the company’s growing influence in addressing serious kidney disorders that have historically had limited therapeutic options.
A significant financial partnership is on the horizon for Semnur Pharmaceuticals, Inc. As iHolding Group LLP has initiated plans for a substantial investment. This agreement, formalized through a binding term sheet on July 3, 2026, sets the stage for iHolding to purchase $100 million …
Please wait processing your request...